搜索
 > 【CD34】重组蛋白信息

CD34信息

英文名称:Hematopoietic progenitor cell antigen CD34
中文名称:造血祖细胞抗原CD34
靶点别称:CD34
上市药物数量:1
临床药物数量:16
最高研发阶段:批准上市

CD34产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
CD4-H5255
Human
Recombinant Human CD34 Protein

CD34 分子别名

CD34,RP11-328D5.2

CD34 分子背景

CD34 molecule is a cluster of differentiation molecule present on certain cells within the human body. It is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly to stromal cells. As a ~ 110 kDa monomeric cell surface antigen, CD34 is highly glycosylated with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain. The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia whereas the L-selectin to which it binds is on the T cell. It was indicated that CD34 is a phosphorylation target for activated PKC, and couples to the hematopoietic adapter protein CrkL, which were involved in CD34 signaling pathways. CD34 is abberantly expressed in many kinds of tumors and is implicated in leukemogenesis.

CD34 参考文献

CD34上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Anti-CD34 mab-sirolimus (OrbusNeich) 批准上市 OrbusNeich 冠状动脉再狭窄 详情

CD34临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Stem cell therapeutics (ExCellThera) ECT-001; ECT-002; ECT-003; ECT-005; ECT-100; UM-171; UM171 + UM092; UM171 + UM390 临床二期 ExCellThera 血液系统恶性肿瘤, 多发性骨髓瘤, 急性骨髓性白血病 详情
Autologous stem cell therapy (Shire) 临床三期 Shire, Caladrius Biosciences 外周血管疾病, 心肌缺血 详情
Dilanubicel (Nohla Therapeutics) NLA-101,NLA 101 临床三期 弗莱德哈钦森癌症研究中心, Nohla Therapeutics 嗜中性粒细胞减少症, 急性辐射综合症, 移植物抗宿主病, 感染类疾病, 血液病 详情
Autologous peripheral blood stem cell therapy (CellProthera) 临床二期 CellProthera 心肌梗塞 详情
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis) 临床一期 University Health Network 法布里病
Elivaldogene tavalentivec (bluebird bio) 临床三期 INSERM, bluebird bio 肾上腺脑白质营养不良 详情
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA) 临床二期 UCLA Biomedical 腺苷脱氨酶缺乏
MB-107 MB-107; IND-14570 临床二期 圣犹达儿童研究医院, National Heart, Lung and Blood Institute, 国家过敏和传染病研究所, 美国国立卫生研究院, Mustang Bio 免疫缺陷性疾病 详情
Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) 临床二期 Genenta Science 多形性成胶质细胞瘤, 多发性骨髓瘤 详情
CLBS-12 CLBS-12 临床二期 Caladrius Biosciences 外周缺血 详情
CD34-mdr1 gene therapy (University of Michigan) AM12M1-MDR1 临床二期 密歇根大学 癌症
GSK-2696277 GSK-2696277,GSK 2696277,GSK2696277 临床二期 Fondazione Telethon, Ospedale San Raffaele, 葛兰素史克 地中海贫血 详情
RTX-134 RTX-134 临床前 Rubius Therapeutics 苯丙酮尿症
shRNA-modified CD34 cell therapy (Kanglin Biotech) 临床一期 康霖生物 艾滋病 详情
CD34 stem cell therapy (LA Childrens Hospital) 临床一期 洛杉矶儿童医院 艾滋病
Alecmestencel-T (Apceth) 临床二期 Apceth 胃肠道肿瘤, 周围动脉闭塞性疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定